(testosterone buccal system)
Striant® (testosterone buccal system) is designed to adhere to the gum or inner cheek. It provides a controlled and sustained release of testosterone through the buccal mucosa as the buccal system gradually hydrates. Insertion of Striant® twice a day, in the morning and in the evening, provides continuous systemic delivery of testosterone.
Striant® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone:
Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range.
Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range.
Media Articles Related to Striant (Testosterone)
Women benefit from testosterone administration after hysterectomy
Source: Endocrinology News From Medical News Today [2013.12.02]
Hysterectomy and oophorectomy (the removal of ovaries) are performed to treat various diseases in women, including cancer. These procedures are accompanied not only by a decline in estrogen but also testosterone levels in the blood. Many women who have undergone surgical removal of their uterus and/or ovaries can develop symptoms of sexual dysfunction, fatigue, low mood and decreased muscle mass.
Study pinpoints optimal testosterone range for longer male lifespan
Source: Endocrinology News From Medical News Today [2013.11.22]
Older men whose testosterone levels were neither low nor high tended to live longer, according to new research accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism.Testosterone is a key male sex hormone involved in maintaining sex drive, sperm production and bone health.
Too Much Testosterone May Be Unhealthy for Older Men
Source: MedicineNet Mens Health Specialty [2013.11.21]
Title: Too Much Testosterone May Be Unhealthy for Older Men
Category: Health News
Created: 11/20/2013 2:36:00 PM
Last Editorial Review: 11/21/2013 12:00:00 AM
Study Raises Questions About Testosterone Therapy
Source: MedicineNet Sleep Apnea Specialty [2013.11.06]
Title: Study Raises Questions About Testosterone Therapy
Category: Health News
Created: 11/5/2013 4:35:00 PM
Last Editorial Review: 11/6/2013 12:00:00 AM
Low Testosterone (Low T)
Source: MedicineNet Hair Loss Specialty [2013.09.26]
Title: Low Testosterone (Low T)
Category: Diseases and Conditions
Created: 12/14/2009 4:15:00 PM
Last Editorial Review: 9/26/2013 12:00:00 AM
Published Studies Related to Striant (Testosterone)
A new combination of testosterone and nestorone transdermal gels for male
hormonal contraception. 
alone or combined with NES gel in suppressing spermatogenesis... CONCLUSION: A combination of daily NES+T gels suppressed sperm concentration to 1
Efficacy and safety of testosterone in the management of hypoactive sexual desire
disorder in postmenopausal women. 
Health... CONCLUSION: Transdermal testosterone appears to be an effective and safe therapy
A placebo-controlled, randomized clinical trial using testosterone undecanoate with injectable norethisterone enanthate: effect on anthropometric, metabolic and biochemical parameters. [2011.12]
Testosterone administered alone or in combination with progestogens in male contraception induces reversible oligo-azoospermia, but its effects on body composition and metabolism are less known. We analysed anthropometric and metabolic parameters in five groups of 10 males: four receiving testosterone undecanoate (TU: 1000 mg) plus norethisterone enanthate (NETE: 200 mg) at different intervals (every 8 weeks: NETE-8; every 12 weeks: NETE-12; every 6 weeks for 12 weeks and then every 12 weeks: NETE-6/12; every 6 weeks for 12 weeks and then TU plus placebo every 12 weeks : NETE-6/12/0) and one placebo (NETE-0/0) for a total of 48 weeks.
A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. [2011.11.17]
Study Type - Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Testosterone deficiency syndrome can be treated with testosterone replacement in the form of injectable, transdermal, buccal and oral preparations. Long-acting i.m. testosterone undecanoate 1000 mg, which is given at 10-14 week intervals, has been shown to be adequate for sustaining normal testosterone levels in hypogonadal men. This study confirms that long-acting i.m. testosterone undecanoate is effective in improving the health-related quality of life in men with testosterone deficiency syndrome as assessed by the improvement in the Aging Male Symptoms scale. Testosterone treatment can be indicated in men who have poor health-related quality of life resulting from testosterone deficiency syndrome. OBJECTIVE: * To evaluate the effect of i.m. injection of testosterone undecanoate 1000 mg over 12 months on the Aging Male Symptom (AMS) scale scores in men with testosterone deficiency syndrome (TDS)... CONCLUSION: * Long-acting testosterone is effective in improving health-related quality of life as assessed by the AMS scale in men with TDS. (c) 2011 THE AUTHORS. BJU INTERNATIONAL (c) 2011 BJU INTERNATIONAL.
A randomized pilot study of monthly cycled testosterone replacement or continuous testosterone replacement versus placebo in older men. [2011.11]
Context: Cycling androgens has been reported by athletes to improve physical performance by enhancing muscle mass and strength, a paradigm that has not been studied, and may have clinical value in older men being treated with testosterone... Conclusions: Cycled testosterone improved body composition and increased muscle strength compared with placebo and increased FSR similarly to continuous testosterone.
Clinical Trials Related to Striant (Testosterone)
A Study of Fortigel Testosterone Gel 2% in Males With Low Testosterone [Active, not recruiting]
Low testosterone is a condition that occurs when the body is unable to produce sufficient
quantities of testosterone. The medical name for low testosterone is hypogonadism.
Hypogonadism can be caused by many factors. Symptoms include: decrease in libido, lack of
energy and mood swings. The goal of testosterone replacement therapy is to return
testosterone levels to the normal range and relieve symptoms.
The purpose of this study is to evaluate the ability of Fortigel testosterone gel 2% to
maintain serum (blood) testosterone levels within the normal range in hypogonadal men aged 18
to 75 years. This will be determined by blood sampling at specified times during the study.
The study is also intended to evaluate the tolerability of Fortigel, which will be applied to
the skin each day throughout the study period.
Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer [Recruiting]
Usually, the male hormone testosterone makes prostate cancer cells grow. Lowering
testosterone usually stops the growth of prostate cancer. However, after a period of time
without testosterone, prostate cancer cells learn to grow again.
You are able to join this trial because your prostate cancer is growing even though you have
very low levels of testosterone. Studies have shown that high doses of testosterone, in this
situation, can cause prostate cancer cells to stop growing.
The investigators did a study several years ago in which the investigators gave high doses
of testosterone to patients such as yourself. The investigators showed that giving
testosterone in this situation was safe. The investigators also showed that the
investigators could, in some cases, make the PSA go down using high-dose testosterone.
The investigators believe that they can improve this type of treatment by combining
testosterone with another drug called dutasteride. Dutasteride is another type of hormone.
It should make testosterone levels rise. The investigators believe that combination of
dutasteride and testosterone will be more a more powerful regimen against your cancer than
Effect of Androgel on Type 2 Diabetic Males With Hypogonadism [Recruiting]
This is to study the effect of replacing testosterone on different inflammatory cells in
type 2 diabetics with low testosterone levels.
Influence of Administration Route of Testosterone on Male Fertility [Not yet recruiting]
Exogenously administered testosterone will override the normal negative feedback of
endogenous testosterone on the hypothalamus and pituitary. Constantly, relatively high and
constant testosterone levels will cause a drop in FSH and LH production by the pituitary.
Since FSH and LH are signalling hormones to the testes, endogenous testosterone production
and spermatogenesis will be down-regulated. It is expected that intranasal dosing in the
morning will mimic the normal physiological pattern of testosterone production thereby
avoiding negative side-effects on spermatogenesis. Trans-dermal gels give testosterone
levels more or less constant over the day and will very likely have inhibitory effects on
The main objective of this study is to show that twice daily intranasal dosing does not
have, or has a smaller inhibitory effect on spermatogenesis in comparison to transdermal
Oral Androgens in Man-4: (Short Title: Oral T-4) [Completed]
The protocol was designed to address the hypothesis that oral testosterone enanthate plus
dutasteride can suppress the secretion of LH and FSH after four weeks of administration. In
addition, we will compare the gonadotropin suppression mediated by a dose of testosterone
enanthate (400 mg twice daily) that would be expected to maintain the serum testosterone in
the normal range throughout the day, with the same dose (800 mg once daily) administered once
daily. This larger once-daily dose is expected to result in a higher peak and lower trough
by the end of the dosing interval